- Home
- AEMD vs GRI Comparison
AEMD vs GRI Comparison
Compare AEMD & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEMD | GRI |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 1.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AEMD | GRI |
|---|---|---|
| Price | $1.96 | $2.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $287.50 | ★ $644.00 |
| AVG Volume (30 Days) | 58.4K | ★ 956.1K |
| Earning Date | 02-12-2026 | 01-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.86 | $2.10 |
| 52 Week High | $53.60 | $311.36 |
Technical Indicators
Market Signals| Indicator | AEMD | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 31.02 | 54.15 |
| Support Level | $2.08 | $2.10 |
| Resistance Level | $2.32 | $2.53 |
| Average True Range (ATR) | 0.19 | 0.53 |
| MACD | -0.05 | -0.11 |
| Stochastic Oscillator | 0.00 | 5.60 |
Price Performance
Historical ComparisonAbout AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.